Market revenue in 2023 | USD 37.4 million |
Market revenue in 2030 | USD 69.2 million |
Growth rate | 9.2% (CAGR from 2023 to 2030) |
Largest segment | Infectious diseases |
Fastest growing segment | Infectious Diseases |
Historical data | 2021 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Infectious Diseases |
Key market players worldwide | Danaher Corp, Kaneka Corp, TriLink BioTechnologies, Apex Biotechnology, BioNTech SE ADR, Lonza Group Ltd, Nunn’s Home Medical Equipment, EQT Corp, Catalent Inc, Samsung Electronics Co Ltd, Biomay AG, Indication, eTheRNA immunotherapies, BioCina |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mrna therapeutics contract development & manufacturing market will help companies and investors design strategic landscapes.
Infectious diseases was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Saudi Arabia mrna therapeutics contract development & manufacturing market based on infectious diseases covering the revenue growth of each sub-segment from 2021 to 2030.
Increasing government support for the vaccines and medicines industry is expected to drive the market over the coming years. For instance, in June 2022, the Minister of Industry and Mineral Resources in Saudi Arabia officially unveiled a range of investment prospects worth USD 3.4 billion in the vaccines and essential pharmaceuticals sector.
These initiatives align with the Kingdom’s objectives of enhancing pharmaceutical and healthcare security. Furthermore, strategic initiatives undertaken by key companies in the market are expected to drive regional market growth.
For instance, in August 2023, CDMO Resilience entered into a joint venture with the Saudi Arabian pharmaceutical firm Lifera to establish a drug product manufacturing facility in Riyadh. The facility aims to manufacture 125 million units yearly, supporting Lifera’s regional product portfolio.
Horizon Databook provides a detailed overview of country-level data and insights on the Saudi Arabia mrna therapeutics contract development & manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Saudi Arabia mrna therapeutics contract development & manufacturing market from 2021 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account